149 related articles for article (PubMed ID: 9076551)
1. Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia.
Zhao SP; Zeng LH
Int J Cardiol; 1997 Feb; 58(3):257-61. PubMed ID: 9076551
[TBL] [Abstract][Full Text] [Related]
2. [Alteration and clinical significance of plasma levels of tumor necrosis factor in chronic heart failure].
Zeng L; Zhao S
Hunan Yi Ke Da Xue Xue Bao; 1998; 23(4):379-81. PubMed ID: 11189399
[TBL] [Abstract][Full Text] [Related]
3. Inappropriately low plasma leptin concentration in the cachexia associated with chronic heart failure.
Murdoch DR; Rooney E; Dargie HJ; Shapiro D; Morton JJ; McMurray JJ
Heart; 1999 Sep; 82(3):352-6. PubMed ID: 10455089
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor-alpha serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure.
Parissis JT; Venetsanou KF; Mentzikof DG; Ziras NG; Kefalas CG; Karas SM
Scand Cardiovasc J; 1999; 33(6):344-50. PubMed ID: 10622546
[TBL] [Abstract][Full Text] [Related]
5. Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system.
Filippatos GS; Tsilias K; Venetsanou K; Karambinos E; Manolatos D; Kranidis A; Antonellis J; Kardaras F; Anthopoulos L; Baltopoulos G
Int J Cardiol; 2000; 76(2-3):117-22. PubMed ID: 11104865
[TBL] [Abstract][Full Text] [Related]
6. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors.
Nagaya N; Uematsu M; Kojima M; Date Y; Nakazato M; Okumura H; Hosoda H; Shimizu W; Yamagishi M; Oya H; Koh H; Yutani C; Kangawa K
Circulation; 2001 Oct; 104(17):2034-8. PubMed ID: 11673342
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure.
Genth-Zotz S; von Haehling S; Bolger AP; Kalra PR; Wensel R; Coats AJ; Anker SD
Am J Cardiol; 2002 Dec; 90(11):1226-30. PubMed ID: 12450603
[TBL] [Abstract][Full Text] [Related]
8. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure.
McMurray J; Abdullah I; Dargie HJ; Shapiro D
Br Heart J; 1991 Nov; 66(5):356-8. PubMed ID: 1747295
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.
Levine B; Kalman J; Mayer L; Fillit HM; Packer M
N Engl J Med; 1990 Jul; 323(4):236-41. PubMed ID: 2195340
[TBL] [Abstract][Full Text] [Related]
10. Elevated tumor necrosis factor alpha of blood mononuclear cells in patients with congestive heart failure.
Zhao SP; Xu TD
Int J Cardiol; 1999 Dec; 71(3):257-61. PubMed ID: 10636532
[TBL] [Abstract][Full Text] [Related]
11. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia.
Milani RV; Mehra MR; Endres S; Eigler A; Cooper ES; Lavie CJ; Ventura HO
Chest; 1996 Oct; 110(4):992-5. PubMed ID: 8874257
[TBL] [Abstract][Full Text] [Related]
12. Adropin and Irisin in Patients with Cardiac Cachexia.
Kalkan AK; Cakmak HA; Erturk M; Kalkan KE; Uzun F; Tasbulak O; Diker VO; Aydin S; Celik A
Arq Bras Cardiol; 2018 Jul; 111(1):39-47. PubMed ID: 29972412
[TBL] [Abstract][Full Text] [Related]
13. The changes of circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy.
Liu L; Zhao SP
Int J Cardiol; 1999 Apr; 69(1):77-82. PubMed ID: 10362376
[TBL] [Abstract][Full Text] [Related]
14. Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis.
Szabó T; Scherbakov N; Sandek A; Kung T; von Haehling S; Lainscak M; Jankowska EA; Rudovich N; Anker SD; Frystyk J; Flyvbjerg A; Pfeiffer AF; Doehner W
Nutr Metab Cardiovasc Dis; 2014 Jan; 24(1):50-6. PubMed ID: 23791298
[TBL] [Abstract][Full Text] [Related]
15. Insights into the pathogenesis of chronic heart failure: immune activation and cachexia.
Anker SD; Rauchhaus M
Curr Opin Cardiol; 1999 May; 14(3):211-6. PubMed ID: 10358792
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin is increased in cardiac cachexia irrespective of body mass index.
Araújo JP; Lourenço P; Rocha-Gonçalves F; Ferreira A; Bettencourt P
Eur J Heart Fail; 2009 Jun; 11(6):567-72. PubMed ID: 19359328
[TBL] [Abstract][Full Text] [Related]
17. Prolonged activation of tumor necrosis factor (TNF)-alpha and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.
Tziakas D; Chalikias G; Parissis JT; Hatzinikolaou H; Stakos D; Papadopoulou E; Kortsaris A; Hatseras D
Eur Cytokine Netw; 2004; 15(3):231-9. PubMed ID: 15542448
[TBL] [Abstract][Full Text] [Related]
18. Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia.
Xin X; Ren AJ; Zheng X; Qin YW; Zhao XX; Yuan WJ; Guo ZF
Peptides; 2009 Dec; 30(12):2281-5. PubMed ID: 19666068
[TBL] [Abstract][Full Text] [Related]
19. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.
Adigun AQ; Ajayi AA
Eur J Heart Fail; 2001 Jun; 3(3):359-63. PubMed ID: 11378008
[TBL] [Abstract][Full Text] [Related]
20. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.
Nishigaki K; Minatoguchi S; Seishima M; Asano K; Noda T; Yasuda N; Sano H; Kumada H; Takemura M; Noma A; Tanaka T; Watanabe S; Fujiwara H
J Am Coll Cardiol; 1997 May; 29(6):1214-20. PubMed ID: 9137215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
